What do branded GLP-1 medications cost without insurance?
The major branded GLP-1 injectable drugs approved for weight management in the United States carry substantial list prices that reflect patent exclusivity and R&D cost recovery. As of mid-2026:
- Wegovy (semaglutide, Novo Nordisk): List price above $1,300/month for the maintenance dose (2.4 mg weekly). Manufacturer savings cards reduce this for commercially insured patients but are subject to eligibility restrictions and program limits.
- Zepbound (tirzepatide, Eli Lilly): List price above $1,000/month. Lilly’s self-pay vial program has offered lower prices at certain doses, but this program is subject to change.
- Ozempic/Mounjaro (diabetes-indicated formulations): Often sought off-label for weight management. List prices are similar; insurance coverage is more variable when not prescribed for the FDA-approved indication.
Manufacturer savings programs, GoodRx, and state patient assistance programs can reduce out-of-pocket cost meaningfully for some patients—but not all. Eligibility gates, income caps, supply constraints, and program expiration create real barriers. For many patients without insurance coverage for GLP-1s, the branded drug is simply out of reach at list price.
Why is compounded GLP-1 so much cheaper?
During an active FDA-designated drug shortage, licensed 503A compounding pharmacies may legally compound shortage-listed drugs under a clinician prescription. Both semaglutide and tirzepatide have appeared on FDA shortage lists, opening a legal compounding pathway.
Compounded semaglutide and tirzepatide are substantially less expensive than their branded counterparts because compounding pharmacies don’t carry the manufacturer’s R&D amortization, sales infrastructure, or branding costs. The price difference is real and significant—often 50–80% less than branded list price.
Compounded GLP-1 cost varies by dose tier because the active pharmaceutical ingredient (API) is priced by quantity. A patient starting on 0.25 mg semaglutide weekly uses far less API than someone on a maintenance dose. Dose-banded pricing structure:
| Dose tier | Relative cost | Typical use |
|---|---|---|
| Starting / titration doses | Lower | 4–8 week hold to confirm tolerability before escalation |
| Mid doses | Moderate | Where many patients stabilize with adequate appetite suppression |
| Maintenance / higher doses | Higher | Still substantially below branded list price |
Total cost of a clinician-supervised program
Evaluating GLP-1 cost without insurance means accounting for the complete program structure, not just the medication:
- Consultation fee:The initial clinician evaluation is a real clinical service. A licensed clinician reviews your health history, BMI, contraindications, and current medications. Most telehealth platforms charge this separately and apply it to your first medication order if you’re approved.
- Monthly medication cost: The compounded injectable prepared by the licensed 503A pharmacy, calibrated to your prescribed dose. This is the largest ongoing cost.
- Follow-up check-ins: Dose adjustments as you move through the titration schedule. Included by some programs, billed separately by others.
- Labs:Some clinicians require or recommend baseline bloodwork, particularly for patients with diabetes risk or thyroid history. Lab costs vary by what’s ordered and your provider.
PepScribe makes consultation and medication pricing transparent before you commit. The consultation fee is separate from the medication cost, clearly disclosed upfront, and goes toward your first month if you’re approved.
Between a licensed 503A pharmacy and a no-prescription vendor, the price gap is really a quality and safety gap — not just a markup.
What compounded does and doesn’t mean
Compounded GLP-1 at a lower price point is not the same as branded GLP-1 at a lower price. Important distinctions:
- Not FDA-approved: No compounded drug product is FDA-approved. Approval belongs to the branded product that went through the NDA process. This is a factual distinction, not a safety judgment about any individual pharmacy.
- Licensed 503A pharmacy compounding: Reputable programs use pharmacies operating under state pharmacy board oversight with pharmaceutical-grade API from FDA-registered suppliers. PepScribe works exclusively with compounding done in the USA by licensed 503A pharmacies. No hidden overseas supply chain.
- Shortage-dependent: The legal basis for compounding semaglutide and tirzepatide depends on FDA shortage status. Shortage determinations can change.
- Clinician prescription required: Any offer of compounded GLP-1 without a clinician evaluation and prescription is operating outside legal channels. No legitimate 503A pharmacy dispenses compounded controlled drugs or injectable peptides without a valid prescription.
The gray market: why cheap without a prescription is a red flag
Some online vendors offer semaglutide or tirzepatide at prices even lower than licensed compounding pharmacies, without requiring a prescription or clinician involvement. These vendors operate outside the legal compounding framework.
The lower price reflects real differences in how the product is made and sourced:
- API from unverified or overseas suppliers with no USP traceability
- No sterility or endotoxin testing requirements
- No dosing accuracy verification
- No clinician oversight or contraindication screening
- No legal recourse if the product is mislabeled or contaminated
Injectable peptides obtained from unregulated sources carry infection risk, dosing risk, and purity risk that licensed pharmacy compounding is specifically designed to prevent. The price gap between gray-market sourcing and licensed compounding represents a real quality and safety gap, not just a markup.
HSA and FSA: applicable for GLP-1 therapy
Health Savings Account (HSA) and Flexible Spending Account (FSA) funds are generally applicable to prescription medications and eligible medical expenses, including the cost of a clinician consultation and prescription GLP-1 medications prescribed for a qualifying medical purpose. This can meaningfully reduce the after-tax cost for patients with HSA or FSA access.
Consult your plan administrator or tax advisor to confirm your specific plan’s rules on GLP-1 medications and telehealth consultation fees.
Frequently asked questions
How much does GLP-1 cost without insurance?
Branded GLP-1 injectables (Wegovy, Zepbound) list above $1,000/month without insurance. Compounded semaglutide or tirzepatide from a licensed 503A pharmacy during a drug shortage period costs a fraction of that. Current compounded pricing varies by dose tier — PepScribe displays exact figures during intake.
Is there a cheaper alternative to Ozempic or Wegovy for weight loss?
Compounded semaglutide from a licensed 503A pharmacy is a substantially less expensive alternative during FDA-designated shortage periods. It contains the same active ingredient but is not the branded product and is not FDA-approved. A clinician prescription is required.
Can I get GLP-1 through telehealth without insurance?
Yes. Telehealth platforms offer clinician evaluation and prescription for GLP-1 therapy without requiring insurance. You pay for the consultation and the compounded medication directly. HSA/FSA funds are often applicable.
Does insurance cover GLP-1 for weight loss?
Coverage is inconsistent. Wegovy is covered by some commercial plans when prescribed for obesity. Ozempic, approved for diabetes, is often covered for that indication but not always for weight management. Zepbound coverage varies widely. Compounded versions are not covered by insurance.
What is the cheapest way to get semaglutide?
Compounded semaglutide from a licensed 503A pharmacy during a drug shortage is significantly less expensive than branded Wegovy at list price. The total cost includes a clinician consultation fee and the medication itself. Avoid unregulated sources — gray-market semaglutide carries serious purity and dosing risks.